Effect of recombinant human thrombopoietin on platelet recovery in patients with multiple myeloma after chemotherapy
Objective To analyze the efficacy and safety of recombinant human thrombopoietin(recombinant human thrombopoietin,rhTPO)in promoting platelet(PLT)recovery after che-motherapy in patients with multiple myeloma(MM).Methods A retrospective analysis was performed on 62 MM patients who developed chemotherapy-associated thrombocytopenia(CIT)within 30 days after chemotherapy from June 2021 to December 2022.According to the use of recombinant human thrombopoietin after chemotherapy,62 patients were divided into rhTPO group(30 cases)and control group(32 cases).The grade of CIT,platelet recovery,platelet transfusion volume during chemotherapy and adverse drug reactions were compared between the two groups.Results There was no significant difference in platelet count before treatment be-tween rhTPO group and control group(P＞0.05),and there was no significant difference in the recovery time of PLT count ≥25 × 109/L(P＞0.05).However,the recovery time of PLT≥ 50 × 109/L and PLT≥100 × 109/L in the rhTPO group were shorter than those in the control group,the PLT after treatment was significantly higher than that in the control group,and the platelet transfusion volume was lower than that in the control group,the differences were statis-tically significant(P＜0.05).The response rate of rhTPO group was 83.3％,PLT of all pa-tients recovered to more than 25 x 109/L,and 2 patients did not reach PLT ≥50 × 109/L.In the control group,the response rate was 78.1％.PLT recovered to more than 25 × 109/L in all patients,and did not reach PLT≥50 × 109/L in 3 patients.No significant adverse reactions were observed in rhTPO group.Conclusion rhTPO can promote platelet recovery and reduce platelet transfusion in MM patients after chemotherapy with good safety.
multiple myelomarecombinant human thrombopoietinchemotherapyplatelet infusionchemotherapy-associated thrombocytopenia
NETL
NSTL
万方数据
